KRRO-121 — Regulatory decision
H2 2026
Regulatory approval for KRRO-121 to initiate clinical trials in the second half of 2026Source filing
KRRO biotech catalysts & pipeline
KORRO BIO INC · Data as of 2026-10-25
Upcoming catalysts
KRRO-121 — NDA/BLA submission
H2 2026
Regulatory filing for KRRO-121 in the second half of 2026Source filing
Undisclosed / early pipeline — IND submission
H2 2026
Nominate development candidate for a third GalNAc-conjugated program in the second half of 2026Source filing
KRRO-111 — NDA/BLA submission
H1 2027
Regulatory submission for KRRO-111 is expected in the first half of 2027.Source filing
KRRO-121 — Interim data
H2 2027
Dosing of UCD patients is expected to start in the first half of 2027, with an interim clinical readout expected in the second half of 2027.Source filing